Aktienanalyse zu Oragenics Inc (OGEN)OGENOragenics Inc

Oragenics, Inc. is a development-stage company. It is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. It focuses on nasal delivery of pharmaceutical medications in neurology and fighting infectious diseases, including drug candidates for treating mild traumatic brain injury (mTBI or Concussion), and for treating Niemann Pick Disease Type C (NPC), and proprietary powder formulation and an intranasal delivery device. Its lead product, ONP-002, is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification. It is also focused on developing medical products that treat brain related illnesses and diseases (the Neurology Assets). Its other product candidate, ONP-001, is in its early stage and clinical trials. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Oragenics Inc is not a good buy right now due to its extremely low RSI of 18.093, indicating it is oversold, and a significant year-to-date decline of 58.18%. The company's financials show consistent net losses, with the latest quarter reporting a net income loss of approximately 2.2 million USD. Additionally, the stock is trading near its 52-week low of 0.34, currently at 0.35, which poses a risk of further declines. The main risk is the negative earnings trend, with EPS consistently in the negative, including -0.57 for Q2 2026. Given these factors, it is advisable to sell rather than buy at this time.